Advertisement
Document › Details
Proteros biostructures GmbH. (8/18/08). "Press Release: Gerhard Müller to Lead Proteros’ Fragement Based Service Offering". Martinsried.
![]() |
Region | Martinsried |
| Country | Germany | |
![]() |
Organisation | Proteros Fragments GmbH |
| Group | Proteros (Group) | |
![]() |
Product | fragment-based drug discovery services |
| Product 2 | structure-based drug design | |
![]() |
Person | Müller, Gerhard (Proteros Biostructures 200808– CSO + Managing Director of Proteros Fragments before GPC Biotech) |
| Person 2 | Neuefeind, Torsten (Proteros Biostructures 200610 Managing Director) | |
Proteros biostructures today announced that Dr. Gerhard Müller has joined the management team to lead the company´s service initiative in fragment based lead generation. Gerhard joins the Proteros group as Chief Scientific Officer and Managing Director of the newly founded 100% subsidiary company Proteros fragments GmbH and has responsibility for the design and further expansion of the company´s in-house compound and fragment library, the fragment evolution process, and the transition into lead optimisation. Gerhard will in this context also work very closely with Mercachem B. V., Proteros´ chemistry partner in the recently announced joint offering regarding structure based lead generation.
Gerhard Müller joins Proteros from GPC Biotech AG where he was, for the last three years Vice President Drug Discovery. In addition to GPC Biotech Gerhard has a demonstrated successful track record in small-molecule drug discovery projects with Glaxo, Bayer AG, and N. V. Organon, where he gained valuable managerial expertise in running entire pre-clinical research departments and project portfolio management responsibilities. In addition, Gerhard developed impressive entrepreneurial skills during the time when he held the position of Chief Scientific Officer at Axxima Pharmaceuticals AG (founded by Axel Ullrich). Gerhard received his Ph.D. in Organic Chemistry in 1992 from the Technical University of Munich, working with Prof Dr. Horst Kessler.
“We are delighted to align the further development of our business with the arrival of such a high calibre science manager to Proteros’ services”, says Torsten Neuefeind, CEO of Proteros, “Gerhard brings a wealth of experience in medicinal chemistry, specifically in fragment based discovery to us, has demonstrated leadership and entertains a very active network in our industry”. “Especially the conceptual combination of medicinal chemistry and structural biology in one business setting has attracted me to Proteros” adds Gerhard Müller, “in addition, I am thrilled by contributing to the development of such a highly regarded company as Proteros in the Life Scienc industry.”
A detailed overview on the services offered is available on www.proteros-fragments.com.
About Proteros biostructures GmbH
Proteros biostructures is a privately held company that provides services and unique technologies for X-ray protein structure analysis and fragment screening to the life science industries. The company acclerates and improves structure analysis and structure-based drug discovery by its expertise, industrialised process and unique technologies, e.g. Free Mounting System™ and Picodropper™, enabling cost-efficient protein-ligand-structure analyses and compound kinetic profiling. Proteros complements its clients’ internal capabilities with its external expertise and access to flexible resources.
Proteros currently provides services to over fifty pharmaceutical and biotechnology companies in North America, Europe and Japan. More information about Proteros can be found on the company’s website at www.proteros.com.
Contacts:
Proteros biostructures GmbH
Torsten Neuefeind, Ph.D.
Chief Executive Officer
Phone: +49 89 700 761-0
Email: business@proteros.com
Or
Proteros fragments GmbH
Gerhard Müller, Ph.D.
Chief Scientific Officer
Phone: +49 89 700761-0
Email: business@proteros-fragments.com
Record changed: 2011-11-27 |
More documents for Proteros (Group)
- [1] Proteros Biostructures GmbH. (8/5/10). "Press Release: Proteros Achieves Growth Rate of more than 30% in 2009 and Announces Expansion of Commercial Organization in USA and Japan". Martinsried....
- [2] Proteros Biostructures GmbH. (3/29/10). "Press Release: Proteros Establishes Board of Directors and Appoints Leading Industry Experts". Martinsried....
- [3] Proteros Biostructures GmbH. (4/6/09). "Press Release: Rigel Pharmaceuticals and Proteros Extend Research Collaboration". Martinsried....
- [4] Proteros Biostructures GmbH. (3/30/09). "Press Release: Axikin and Proteros Enter into Fragment-based Lead Discovery Collaboration". San Diego, CA & Martinsried....
- [5] Proteros Biostructures GmbH. (3/25/09). "Press Release: Dr. Dirk Ullmann Joins Proteros Biostructures as Chief Scientific Officer". Martinsried....
- [6] Proteros Biostructures GmbH. (3/6/09). "Press Release: Proteros Biostructures Collaboration with UCB". Martinsried....
- [7] Proteros Biostructures GmbH. (8/22/07). "Press Release: Proteros Biostructures Raises 5.2 Million Euros for Business Expansion". Martinsried....
To subscribe to our free, monthly [MSC] Newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
NEW: Visit our brand new forthcoming web portals Life-Sciences-Germany.com and Life-Sciences-Europe.com
» top
![[MSC] Mass-Spec-Capital.com The Mass Spectrometry Web Portal](/images/basics/msc-mass-spectrometry-portal-logo.jpg)









![Banner [iiito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)